Researchers from the University of Copenhagen have discovered a new weight loss drug target that works without causing nausea ...
A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...
An update from Vivani Medical ( (VANI) ) is now available. Vivani Medical is advancing its innovative GLP-1 implant technology to address ...
The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...
Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...
Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...
A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...
Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...
In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite.
Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
WEDNESDAY, Nov. 13, 2024 (HealthDay News) -- The blockbuster GLP-1 drug semaglutide ( Ozempic, Wegovy) could curb drinking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback